Pharmacokinetics and brain penetration study of chlorogenic acid in rats

1. The present study is designed to investigate the brain distribution and plasma pharmacokinetics profiles of chlorogenic acid (CGA) after intranasal administration in Charles–Foster rats to evaluate whether the CGA molecules are transported directly via the nose-to-brain path.

2. The CGA is administered intravenously (IV) and intranasally (IN) at the dose of 10?mg/kg. Further, its concentration in the plasma, cerebrospinal fluid (CSF) and the whole brain is analyzed by HPLC-UV method.

3. The study observes that CGA is rapidly absorbed in plasma with t_max of 1?min similar to IV route after IN administration. The peak plasma concentration and AUC_0–24 are higher by 3.5 and 4.0 times respectively in IV administration, compared to IN delivery that represents the significant less systemic exposure of CGA in IN route.

4. However, the concentration of CGA in the brain is 4, 6.5, 5.3, 5.2 and 4.5 times higher at 30, 60, 120, 240 and 360?min, respectively in IN administration compared to IV administration. The exposure of CGA in the brain after IN administration (AUC_{brain, IN}) was significantly greater (4 times) as compared to the exposure of CGA in the brain (AUC_{brain, IV}) after IV administration reflecting significant brain uptake of CGA through nasal route. Therefore, IN delivery of CGA can be a promising approach for the treatment of stroke and neurodegenerative disorders.     

Antihepatotoxic Effects of chlorogenic acid from Anthocephalus cadamba

In the present study, chlorogenic acid (CGA) isolated from Anthocephalus cadamba was screened for hepatoprotective activity by in vitro and in vivo assay methods using carbon tetrachloride (CCl₄) as a model of liver injury. Intraperitoneal administration of CGA to mice at a dose of 100 mg/kg body weight for 8 days caused significant reversal in lipid peroxidation, enzymatic leakage, cytochrome P450 (Cyt P450) inactivation and produced enhancement of cellular antioxidant defence in CCl₄-intoxicated mice, revealing that the antioxidative action of CGA is responsible for its liver protective activity. CGA exhibited a better therapeutic protective action than silymarin (SM), in CCl₄-administered mice.     

小儿牛黄散有效成分的HPLC定量

用反相HPLC法测定小儿牛黄散中小檗碱、巴马汀、大黄素、绿原酸的含量。用甲醇提取散剂样品,在ODS柱上,用外标法在各自特征吸收处测定。此法具有分离好、灵敏度高、重现性强、操作简单等优点。     

双黄连气雾剂稳定性的研究

采用高压液相色谱法测定了双黄连气雾剂中绿原酸与黄芩甙的含量,应用恒温加速实验法探讨了双黄连气雾剂的化学动力学过程,预测其稳定性,实验结果与留样观察法相近,同时对双黄连在降解过程中pH的变化进行了考察。     

Development of a High-Throughput Method to Study the Inhibitory Effect of Phytochemicals on Trimethylamine Formation

Choline is metabolized by the gut microbiota into trimethylamine (TMA), the precursor of pro-atherosclerotic molecule trimethylamine N-oxide (TMAO). A reduction in TMA formation has shown cardioprotective effects, and some phytochemicals may reduce TMA formation. This study aimed to develop an optimized, high-throughput anaerobic fermentation methodology to study the inhibition of choline microbial metabolism into TMA by phenolic compounds with healthy human fecal starter. Optimal fermentation conditions were: 20% fecal slurry (1:10 in PBS), 100 µM choline, and 12 h fermentation. Additionally, 10 mM of 3,3-dimethyl-1-butanol (DMB) was defined as a positive TMA production inhibitor, achieving a ~50% reduction in TMA production. Gallic acid and chlorogenic acid reported higher TMA inhibitory potential (maximum of 80–90% TMA production inhibition), with IC₅₀ around 5 mM. Neither DMB nor gallic acid or chlorogenic acid reduced TMA production through cytotoxic effects, indicating mechanisms such as altered TMA-lyase activity or expression.     

广山楂HPLC指纹图谱建立及其活血化瘀作用谱效关系研究

目的 建立广山楂Malus doumeri指纹图谱,测定各批次广山楂的“活血化瘀”药效学指标,探讨广山楂化学成分与活血化瘀功效的谱效关系。方法 采用HPLC法建立18批广山楂的指纹图谱。利用大鼠高脂模型,测定不同批次广山楂的“活血化瘀”药效学指标,包括高密度脂蛋白胆固醇（high density lipoprotein cholesterol,HDL-C）、低密度脂蛋白胆固醇（low density lipoprotein cholesterin,LDL-C）、总胆固醇（total cholesterol,TC）、三酰甘油（triglyceride,TG）含量及血液流变学指标等。运用偏最小二乘回归法（partial least-square method regression,PLSR）、灰色关联度分析法,分析广山楂化学成分与活血化瘀药效指标间的谱效关系。结果 构建了广山楂的HPLC图谱,确定了6个共有峰,并指认了其中的2个共有峰（绿原酸、根皮苷）。活血化瘀实验表明,不同批次广山楂活血药效指标间具有明显差异,在标定的广山楂6个特征峰中,峰2～6与HDL-C呈正相关,峰1、5、6与LDL...     

基于UHPLC-QTOF-MS/MS和分子对接筛选紫菀中润肠通便的效应

目的 通过UHPLC-QTOF-MS/MS和分子对接技术阐明紫菀Aster tataricus中润肠通便作用的效应成分。方法 采用UHPLC-QTOF-MS/MS技术分析体内肠道内容物的成分,再利用SYBYL-X 2.0与Discovery Studio 4.0分子对接软件研究肠道内容物成分与M2受体、M3受体、蛋白激酶C(protein kinase C,PKC)蛋白的相互作用,明确各成分与靶标蛋白的结合强度。结果 体内肠道内容物中共鉴定出28个紫菀中的化学成分,有10个成分均可与M2受体、M3受体及PKC蛋白分子对接较好,其中astin J与3种靶标蛋白结合的平均打分值最高,这些成分均以非共价键方式与靶标蛋白结合,产生氢键、范德华力、经典作用力等相互作用。结论 紫菀中的astin J、asterin F、asterin A、异绿原酸A、异绿原酸B、异绿原酸C、绿原酸、槲皮素、山柰酚和木犀草素共10个成分可能是通过调节M受体及其下游信号通路PKC蛋白的表达发挥润肠通便的作用。     

UPLC指纹图谱多模式识别结合多指标成分测定的清热消炎宁胶囊质量控制研究

目的 建立清热消炎宁胶囊（Qingre Xiaoyanning Capsules,QXC）UPLC指纹图谱及多指标成分定量分析方法,结合化学模式识别技术对多批次制剂进行质量评价。方法 通过优化样品前处理及色谱检测方法,建立合适UPLC指纹图谱和含量测定条件。色谱柱为UPLC HSS T3柱（50 mm×2.1 mm,1.8μm）;乙腈-0.1%甲酸水溶液为流动相梯度洗脱;检测波长280 nm;柱温40℃;体积流量0.5 mL/min。采用层次聚类分析（hierarchical cluster analysis,HCA）、主成分分析（principal component analysis,PCA）、正交偏最小二乘-判别分析（orthogonal partial least squares-discriminant analysis,OPLS-DA）和聚类热图分析对20批清热消炎宁胶囊进行质量评价。结果 清热消炎宁胶囊UPLC指纹图谱及含量测定方法学考察结果均符合测定要求,获得21个共有峰,运用对照品比对方式指认了7个色谱峰;20批样品的相似度均大于0.954,样品间一致性及稳定性良好;...     

基于指纹图谱及非挥发性成分定量结合化学模式识别法评价不同产地艾叶质量

目的 以非挥发性化学成分为指标,评价不同产地艾叶Artemisia argyi质量,为其进一步开发利用提供科学依据。方法 采用高效液相色谱法（high-performance liquid chromatography,HPLC）,以指纹图谱定性,绿原酸和黄酮等多指标成分定量,结合聚类分析（hierarchical cluster analysis,HCA）、主成分分析（principal component analysis,PCA）和正交偏最小二乘法-判别分析（orthogonal partial least squares-discriminant analysis,OPLS-DA）对艾叶进行化学模式识别研究。结果 建立了20批艾叶的指纹图谱,相似度为0.739～0.983,标定了28个共有峰,指认了绿原酸、木犀草苷、圣草酚、棕矢车菊素、异泽兰黄素5个成分,含量测定表明不同产地艾叶绿原酸和黄酮成分存在显著差异;HCA分析20批艾叶为3类;PCA得到7个主成分的累积方差贡献率为86.676%;OPLS-DA分析表明绿原酸、木犀草苷、圣草酚、棕矢车菊素、异泽兰黄素可能是影响艾叶药材质量的差异标志物。结论 指纹图谱定性及多非挥发性成分定量结合化学模式识别可用于艾叶药材鉴别和质量控制。     

正交试验法优选银翘解毒软胶囊的水煮提取工艺

采用Ｌ９（３＾４）正交设计,以浸膏得率,正丁醇浸出率,绿原酸含量为考察指标,优选银翘解毒软胶囊的水煮提取工艺。结果表明：最佳提取工艺为首次加１０倍量水,浸泡３０ｍｉｎ,煎煮２ｈ,第２次加８倍量水,煎煮１．５ｈ。